


# *Testing and Precision Therapies*

## Can Health Systems Integrate Drug and Diagnostic Access in Uncertain Times?



The Canadian Association for Population Therapeutics (CAPT) Conference

October 17, 2022

Panel Session 4 @ 3:15pm to 4:30pm

Toronto, Ontario

[capt-actp.ca](http://capt-actp.ca)

# Panel Members

<b>Barry Stein</b>	President/CEO, Colorectal Cancer Canada
<b>Harriet Feilotter</b>	Professor, Department of Pathology & Molecular Medicine, Queens University
<b>Craig Ivany</b>	Chief Provincial Diagnostics Officer, Provincial Health Services Authority, British Columbia
<b>Don Husereau</b>	Adjunct Professor, University of Ottawa

# Testing & Precision Medicines

***Personalized healthcare and precision medicines aim to develop and deliver treatments that are guided by the molecular characteristics of an individual's tumour to improve outcomes for each patient.***

The characterization of the patient's tumor biology testing for biomarkers through Comprehensive Genomic Testing (CGP) or otherwise can inform a diagnosis, prognosis, and treatment to improve patient outcomes.

However, treatments matched based on these tests are typically identified in only 5-10% of patients, and usually no more than 20%.

# Testing & Precision Medicines

**For precision cancer care based to be fully realized:**

- i. It must be available to more cancer patients, in a timely and equitable manner.
- ii. High quality data around testing for these biomarkers is necessary.

Healthcare systems can be optimized to do so, by both improving the physical and organizational structure for access to testing and drugs, and the process that cancer care is delivered.



# BIOTECanada & Innovative Medicines Canada

## POLICY PAPER

*To enhance system-wide preparedness for innovative diagnostic testing to improve health, build healthcare infrastructure including reliable domestic supply, and position Canada to benefit from future research and development investments, we need to:*

### **1. Enhance Publicly Funded Testing to Support all Canadians**

Testing is a critical component of health care that transcends drug reimbursement and should be available to all Canadians.

### **2. Coordinate and Anticipate Future Needs**

To address patient needs, funders need a holistic system view to health technology management with a focus on coordinating disconnected service pathways.

### **3. Transparency and Accountability**

Transparency regarding access and funding of diagnostics and accelerating access to targeted therapies.

# BIOTECanada & Innovative Medicines Canada

## POLICY PAPER

[Optimizing Patient Access to Precision Therapies:](#)  
[Preparing for the Emerging Era of Advanced Testing](#)

### 4. Context-Specific HTA

HTA should be addressed at the provincial level. Evaluation will require HTA processes that are closely linked to communities of practice and consider local care pathways, data availability.

### 5. Priority Setting Driven by Patient and Health System Needs

We need to move beyond traditional budget silos to align resources within provincial health ministries (e.g., between drug plans & diagnostic funding).

### 6. Adopt an approach with the goal of simultaneous public funding of diagnostic tests and precision medicines, along with clarity on the integrated and supportive role that medicine manufacturers play in the process.

## PANEL QUESTIONS

*Considering the core principles of the BioteCanda & IMC Policy, how can we better deliver on the promise of precision medicines?*

- a. (i) How can we better adapt the physical and organizational structures our provincial healthcare systems to ensure more cancer patients benefit from access to testing and hence precision medicines in a timely manner?
  
- (ii) Considering the process that cancer care is delivered, is it realistic to say that all cancer patients should be tested, regardless of where they live in Canada? Who should pay for it?

## PANEL QUESTIONS

*Considering the core principles of the BioteCanda & IMC Policy, how can we better deliver on the promise of precision medicines?*

- b. There is need for closer and more *integrated collaboration* among the many stakeholders to ensure a holistic approach to ensure equitable and timely access to testing.
  - (i) What would you recommend as a practical first step towards achieving this collaboration between stakeholders?

## PANEL QUESTIONS

*Considering the core principles of the BioteCanda & IMC Policy, how can we better deliver on the promise of precision medicines?*

- c. In each province, the process of *securing funding* and allowing access to testing for patients could improve with more *transparency and accountability*.
  - (i) What is one key recommendation you have for those involved decision makers to work towards this?
  - (ii) Who should order these tests, and who should pay for them?

## PANEL QUESTIONS

*Considering the core principles of the BioteCanda & IMC Policy, how can we better deliver on the promise of precision medicines?*

d. From the perspective of your Province are there an *aspect(s) of the process that cancer care is delivered that you think your own province (or other province) does well or better than others* to ensure timely and equitable access to testing and precision medicines?

# QUESTIONS?



# THANK YOU!

